<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283942</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-256R</org_study_id>
    <nct_id>NCT04283942</nct_id>
  </id_info>
  <brief_title>Effect of Intermittent Calorie Restriction on NAFLD Patients With Disorders of Glucose Metabolism</brief_title>
  <official_title>Effect of Intermittent Calorie Restriction on Non-alcoholic Fatty Liver Disease Patients With Disorders of Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting
      2 days each week) on liver fat content in NAFLD patients with abnormal blood glucose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent caloric restriction (ICR) can effectively reduce weight and facilitate blood
      glucose control, but whether it can be applied for clinical treatment to non-alcoholic fatty
      liver disease (NAFLD) patients remains unclear. What's more, in order to investigate whether
      the mechanism of glucose-lowering effect of ICR is related to the decrease of liver fat
      content, we intend to carry out this study in NAFLD patients with abnormal glucose
      metabolism. It is an open-labeled randomized trial designed to observe the effect of 5:2
      intermittent calorie restriction (fasting 2 days each week) on liver fat content in NAFLD
      patients with abnormal blood glucose. 50 patients will be randomly divided into ICR group and
      control group for 12 weeks of intervention. ICR group: during the 2-day fasting-mimicking
      period each week, the food based on plant ingredients will be served (4 pieces of nutrition
      bars / day, 1:2:1 for breakfast, lunch and dinner, 124.4kcal / piece, 497.2kcal / day in
      total). In the rest 5 days each week, subjects are allowed ad libitum to their usual food.
      Control group: under the guidance of nutritionist, subjects have to learn the method of food
      calories calculation. The daily calories intake for control group should be: 25 kcal / kg ×
      standard weight [kg, male: height (cm) - 105, female: height (cm) - 100]. Daily food diary is
      required in both groups. During the experiment, all subjects should maintain their exercise
      routine. The use of drugs affecting blood glucose and fatty liver should be avoided. After 12
      weeks of intervention, the changes of liver fat content were evaluated by magnetic resonance
      spectroscopy (MRS), magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and
      quantitative ultrasound method. The effects of ICR on body weight, blood glucose, body fat
      distribution and appetite will also be evaluated. Both groups will be followed up on their
      changes of weight 4 weeks after intervention.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were randomly divided into intermittent calorie restriction group and control group for 12 weeks of intervention. Both groups will be followed up 4 weeks after intervention.
ICR group: during the 2-day fasting-mimicking period each week, the food based on plant ingredients will be served (4 pieces of nutrition bars / day, 1:2:1 for breakfast, lunch and dinner, 124.4kcal/piece, 497.2kcal / day in total). In the rest 5 days each week, subjects are allowed ad libitum to their usual food.
Control group: under the guidance of nutritionist, subjects have to learn the method of food calories calculation. For each day, the daily calories intake = 25 kcal / kg × standard weight [kg, male: height (cm) - 105, female: height (cm) - 100].</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of liver fat content in %</measure>
    <time_frame>12 weeks</time_frame>
    <description>The changes of liver fat content were evaluated by magnetic resonance spectroscopy (MRS), magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and quantitative ultrasound method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of fasting and 2h postload blood glucose in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of HbA1c in % and proportion of those HbA1c&lt;7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of liver enzymes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of liver enzymes (alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transpeptidase in IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of lipid profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in serum lipid profile (serum triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol in mmol/L)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of body fat distribution</measure>
    <time_frame>12 weeks</time_frame>
    <description>Human body composition will be detected by dual‐energy X‐ray absorptiometry (DXA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of controlled attenuation parameter value and liver stiffness measure of liver transient elastography</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of controlled attenuation parameter value and liver stiffness measure of liver transient elastography</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of fasting and postprandial C-peptide</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change of fasting and postprandial C-peptide in ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of brain functional MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Brain functional MRI will be used to evaluate the change of appetite</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease (NAFLD)</condition>
  <condition>Disorders of Glucose Metabolism</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Impaired Glucose Regulation</condition>
  <arm_group>
    <arm_group_label>Intermittent Calorie Restriction (ICR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eat only instant nutrition bar in two consecutive days each week, 4 sticks / day, 1 for breakfast, 2 for lunch, 1 for dinner. And the total caloric intake is 497.2kcal/day. In the rest 5 days each week, subjects are allowed ad libitum to their usual food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Followed by NAFLD guidelines' recommendation of 25 kcal / kg / day, we only ask them to adjust their daily diet. No experimental foods or drugs are supplied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intermittent caloric restriction</intervention_name>
    <description>Intermittent calorie restriction is a new strategy of reducing weight and improving health. The most common ICR methods include alternative day calorie restriction (ACR) and 5:2 intermittent fasting (fasting 2 days each week). The food consumption in non-fasting day is not limited. We plan to apply the 5:2 intermittent fasting. Intermittent caloric restriction can effectively reduce weight, improve body composition (i.e., reduce fat content while maintaining lean body weight), reduce risk factors of cardiovascular disease (including reducing blood pressure, improving blood lipid level, reducing oxidative stress), and also facilitate blood glucose control (by increasing insulin sensitivity and improving the function of islet β cells).</description>
    <arm_group_label>Intermittent Calorie Restriction (ICR)</arm_group_label>
    <other_name>Intermittent fasting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>25kcal/kg/d diet</intervention_name>
    <description>For each day, the daily calories intake = 25 kcal / kg × standard weight [kg, male: height (cm) - 105, female: height (cm) - 100].</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70

          2. The controlled attenuation parameter (CAP) value of liver transient elastography ≥250
             dB / M (for diagnosis of fatty liver)

          3. BMI≥24 kg/m2

          4. The diagnostic criteria for abnormal glucose metabolism are as follows (meeting at
             least one):

               1. Impaired glucose regulation: fasting blood glucose ≥ 5.6 mmol / L, postprandial
                  blood glucose ≥ 7.8 mmol / L or HbA1c ≥ 5.7%.

               2. Diabetes mellitus: diabetic symptoms + plasma glucose concentration ≥ 11.1 mmol /
                  L at any time or fasting plasma glucose concentration ≥ 7.0 mmol / L or OGTT 2 h
                  plasma glucose concentration ≥ 11.1 mmol / L.

        Exclusion Criteria:

          1. Type 1 diabetes, gestational diabetes and other special types of diabetes

          2. Poor blood glucose control, HbA1c &gt; 8.5% within 3 months

          3. Had antidiabetic drugs in the past month

          4. Serum ALT was more than 6 times of normal upper limit

          5. Excessive alcohol consumption (definition: in the past 6 months, alcohol intake: men &gt;
             140g, women &gt; 70g)

          6. Other liver diseases: such as acute and chronic viral hepatitis, drug-induced
             hepatitis, immune hepatitis, liver cirrhosis, liver cancer, etc

          7. Had drugs that may affect NAFLD in the past three months, such as vitamin E

          8. Biliary diseases: biliary obstructive diseases, etc

          9. Other diseases affecting glycolipid metabolism: hyperthyroidism, hypothyroidism,
             Cushing's syndrome, etc

         10. Chronic kidney disease (serum creatinine ≥ 2.0mg/dl)

         11. Life expectancy of no more than 5 years

         12. Already pregnant or plan to be pregnant in the near future

         13. Mental illness

         14. Other conditions affecting follow-up

         15. Participated in other clinical trials in the past 4 weeks

         16. Absent of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Bian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Gao</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Bian</last_name>
    <phone>+8613681976102</phone>
    <email>bianhuaer@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongmei Yan</last_name>
    <phone>+8613761666976</phone>
    <email>yan.hongmei@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hua Bian</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. Review.</citation>
    <PMID>26707365</PMID>
  </reference>
  <reference>
    <citation>Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017 Oct;67(4):862-873. doi: 10.1016/j.jhep.2017.06.003. Epub 2017 Jun 19. Review.</citation>
    <PMID>28642059</PMID>
  </reference>
  <reference>
    <citation>Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:11-7. doi: 10.1111/jgh.12036. Review.</citation>
    <PMID>23855290</PMID>
  </reference>
  <reference>
    <citation>Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014 Dec;60(6):2099-108. doi: 10.1002/hep.27406. Epub 2014 Oct 29. Review.</citation>
    <PMID>25164003</PMID>
  </reference>
  <reference>
    <citation>Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002 Apr 18;346(16):1221-31. Review.</citation>
    <PMID>11961152</PMID>
  </reference>
  <reference>
    <citation>Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264. Review.</citation>
    <PMID>26667191</PMID>
  </reference>
  <reference>
    <citation>Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002 Jun;51(6):1889-95.</citation>
    <PMID>12031978</PMID>
  </reference>
  <reference>
    <citation>Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014 Mar;59(3):1174-97. doi: 10.1002/hep.26717. Epub 2014 Jan 16. Review.</citation>
    <PMID>24002776</PMID>
  </reference>
  <reference>
    <citation>Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014 Jul 22;11(7):e1001680. doi: 10.1371/journal.pmed.1001680. eCollection 2014 Jul. Review.</citation>
    <PMID>25050550</PMID>
  </reference>
  <reference>
    <citation>Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005 May;100(5):1072-81.</citation>
    <PMID>15842581</PMID>
  </reference>
  <reference>
    <citation>Sundfør TM, Svendsen M, Tonstad S. Intermittent calorie restriction-a more effective approach to weight loss? Am J Clin Nutr. 2018 Nov 1;108(5):909-910. doi: 10.1093/ajcn/nqy288.</citation>
    <PMID>30475966</PMID>
  </reference>
  <reference>
    <citation>Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017 Feb 15;9(377). pii: eaai8700. doi: 10.1126/scitranslmed.aai8700.</citation>
    <PMID>28202779</PMID>
  </reference>
  <reference>
    <citation>Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH, Cohen P, Sneddon JB, Perin L, Longo VD. Fasting-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration to Reverse Diabetes. Cell. 2017 Feb 23;168(5):775-788.e12. doi: 10.1016/j.cell.2017.01.040.</citation>
    <PMID>28235195</PMID>
  </reference>
  <reference>
    <citation>Johari MI, Yusoff K, Haron J, Nadarajan C, Ibrahim KN, Wong MS, Hafidz MIA, Chua BE, Hamid N, Arifin WN, Ma ZF, Lee YY. A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease. Sci Rep. 2019 Aug 2;9(1):11232. doi: 10.1038/s41598-019-47763-8. Erratum in: Sci Rep. 2020 Jun 25;10(1):10599.</citation>
    <PMID>31375753</PMID>
  </reference>
  <reference>
    <citation>Schübel R, Nattenmüller J, Sookthai D, Nonnenmacher T, Graf ME, Riedl L, Schlett CL, von Stackelberg O, Johnson T, Nabers D, Kirsten R, Kratz M, Kauczor HU, Ulrich CM, Kaaks R, Kühn T. Effects of intermittent and continuous calorie restriction on body weight and metabolism over 50 wk: a randomized controlled trial. Am J Clin Nutr. 2018 Nov 1;108(5):933-945. doi: 10.1093/ajcn/nqy196.</citation>
    <PMID>30475957</PMID>
  </reference>
  <reference>
    <citation>Liu M, Yan HM, Gao X, Gao J. [Association of abnormality of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease]. Zhonghua Yi Xue Za Zhi. 2007 Jan 23;87(4):253-5. Chinese.</citation>
    <PMID>17425870</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Hua Bian</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Non-Alcoholic Fatty Liver Disease</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

